Clopidogrel 75 Biotech 75 mg FC Tablet
PDF Leaflet Revision Date: 06 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Reduction of atherosclerotic events in patients with symptomatic atherosclerotic disease.
Dosage (summary)
One tablet daily, with or without food.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy and lactation; safety not established.
Key Drug Interactions
- NSAIDs
- Warfarin
- CYP2C19 inhibitors
Contraindications
- Hypersensitivity to clopidogrel
- Active bleeding
- Severe liver impairment
Common side effects
- Bleeding
- Thrombocytopenia
- Gastrointestinal hemorrhage
Counselling Points
- Report unusual bleeding
- Discontinue 7 days before surgery
- Inform healthcare providers of clopidogrel use
Serious warnings
- Risk of Thrombotic Thrombocytopenic Purpura (TTP)
- Increased bleeding risk
Important Disclaimer
The Clopidogrel 75 Biotech 75 mg FC Tablet professional information leaflet below is the property of Biotech Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
